Septerna, Inc. (SEPN)
Nasdaq · Healthcare · Biotechnology
$37.87+0.42%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.8B
- 52-week range
- $17.55 – $51.10
- 52-week change
- +79.49%
- EPS (trailing)
- −$0.54
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $46.0M (+4174.51%)
- Net income
- −$48.9M
- Operating margin
- −148.6%
- Diluted EPS
- −$1.10
- Free cash flow
- $110M
From the company’s annual report on SEC EDGAR.
About Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Headquarters: South San Francisco, United States · 123 employees · septerna.com